|Dr. Taylor H. Schreiber M.D., Ph.D.||Co-Founder, CEO & Director||526.11k||N/A||1980|
|Dr. Arundathy Nirmalini Pandite M.B.A., M.D.||Chief Medical Officer||583k||N/A||1959|
|Ms. Casi DeYoung||Chief Bus. Officer||440.66k||N/A||1971|
|Mr. Andrew R. Neill M.B.A.||Chief Financial Officer||N/A||N/A||1986|
|Conor Richardson||Sr. Director of Fin. & Investor Relations||N/A||N/A||N/A|
|Dr. Abhinav A. Shukla Ph.D.||Chief Technical Officer||N/A||N/A||N/A|
|Ms. Erin Ator Thomson J.D.||Gen. Counsel||N/A||N/A||1980|
|Dr. Thomas Lampkin Pharm.D.||Head of Regulatory Affairs||N/A||N/A||N/A|
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs, Inc.’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 8; Compensation: 9.